Abstract |
Our aim was to determine whether lipoprotein lipase gene PvuII polymorphism can be considered as an independent risk factor for coronary artery disease (CAD) by conducting a meta-analysis of all available published trials, including our own study. In 7 seperate studies, 3289 subjects were screened for this substitution; meta-analysis included only some of these individuals. Among the 7 studies, 6 were performed on white subjects, whereas 1 was on patients with Saudi Arabic descent.Subgroup analysis indicated that individuals with PvuII substitution does not have an increased risk for CAD. The LPL-PvuII genotype and allele frequency distributions did not differ significantly between CAD patients and healthy controls. There was no difference in the distribution of LPL-PvuII genotypes between the healthy subjects and the patients with CAD. However, no significant differences in lipid variables ( triglyceride and HDL-cholesterol) were determined for the PvuII polymorphisms in the patients with CAD. No significant differences were found in serum triglyceride and HDL-cholesterol levels for LPL-PvuII genotypes when the control and CAD groups were pooled. In conclusion, LPL-Pvu II polymorphism cannot be used as independent genetic risk factor for CAD.
|
Authors | Penbe Cagatay, Belgin Susleyici-Duman, Cavlan Ciftci |
Journal | Disease markers
(Dis Markers)
Vol. 23
Issue 3
Pg. 161-6
( 2007)
ISSN: 0278-0240 [Print] United States |
PMID | 17473385
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Lipids
- Lipoprotein Lipase
- CAGCTG-specific type II deoxyribonucleases
- Deoxyribonucleases, Type II Site-Specific
|
Topics |
- Case-Control Studies
- Coronary Artery Disease
(blood, genetics)
- Deoxyribonucleases, Type II Site-Specific
- Genetic Predisposition to Disease
- Humans
- Lipids
(blood)
- Lipoprotein Lipase
(genetics)
- Polymorphism, Genetic
|